Regeneron Q3 revenue tops estimates on Sanofi Dupixent profit; shares rise 4%

Regeneron Pharmaceutical's shares rose 4% in premarket trading following the company's Q3 earnings report, which surpassed Wall Street estimates. Adjusted earnings of $20.07 per share and revenue of $5.12 billion were both higher than the expected $16.06 per share and $4.54 billion, respectively. The surge in payments from partner Sanofi on Dupixent was the primary driver, with revenue from the drug increasing by 68% to $2.72 billion.

Sales of Regeneron's older eye drug Eylea fell 41% to $400 million, as competition and patient migration to Eylea HD reduced volumes. The company raised its 2026 forecast for research and development expenses and adjusted gross margin, and is awaiting an FDA decision on cemdisiran for generalized myasthenia gravis.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.